Company Description
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders.
Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.
The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients.
Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
| Country | United States |
| IPO Date | Jan 31, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 23 |
| CEO | Carrie L. Bourdow |
Contact Details
Address: 955 Chesterbrook Boulevard Chesterbrook, Pennsylvania United States | |
| Website | https://www.trevena.com |
Stock Details
| Ticker Symbol | TRVN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001429560 |
| CUSIP Number | 89532E109 |
| ISIN Number | US89532E2081 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Carrie L. Bourdow | President, Chief Executive Officer & Chairman |
| Barry Shin J.D. | Chief Operating Officer |
| Dr. Howard A. Rockman M.D. | Scientific Founder, Consultant and Member of Scientific Advisory Board |
| Dr. Mark A. Demitrack M.D. | Senior Vice President & Chief Medical Officer |
| Katrine Sutton | Principal Financial Officer & principal accounting officer |
| Michael Catalano | Vice President of Marketing |
| Robert T. Yoder | Senior Vice President, Chief Business Officer, Head of Commercial Operations & Chief Compliance Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 06, 2024 | 3 | Filing |
| Nov 29, 2024 | RW | Filing |
| Nov 27, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 07, 2024 | 10-Q | Quarterly Report |
| Nov 07, 2024 | 8-K | Current Report |
| Oct 10, 2024 | 4 | Filing |
| Oct 10, 2024 | 4 | Filing |
| Oct 10, 2024 | 4 | Filing |
| Oct 10, 2024 | 8-K | Current Report |